Immunostimulatory DNA and oligodeoxynucleotides containing unmethylated CpG motifs (CpG DNA) are strongly stimulatory for B cells and antigen-presenting cells (APCs). We report here that, as manifested by CD69 and B7-2 upregulation, CpG DNA also induces partial activation of T cells, including naive-phenotype T cells, both in vivo and in vitro. Under in vitro conditions, CpG DNA caused activation of T cells in spleen cell suspensions but failed to stimulate highly purified T cells unless these cells were supplemented with APCs. Three lines of evidence suggested that APC-dependent stimulation of T cells by CpG DNA was mediated by type I interferons (IFN-I). First, T cell activation by CpG DNA was undetectable in IFN-IR−/− mice. Second, in contrast to normal T cells, the failure of purified IFN-IR−/− T cells to respond to CpG DNA could not be overcome by adding normal IFN-IR+ APCs. Third, IFN-I (but not IFN-γ) caused the same pattern of partial T cell activation as CpG DNA. Significantly, T cell activation by IFN-I was APC independent. Thus, CpG DNA appeared to stimulate T cells by inducing APCs to synthesize IFN-I, which then acted directly on T cells via IFN-IR. Functional studies suggested that activation of T cells by IFN-I was inhibitory. Thus, exposing normal (but not IFN-IR−/−) T cells to CpG DNA in vivo led to reduced T proliferative responses after TCR ligation in vitro.
Skip Nav Destination
Article navigation
21 December 1998
Article|
December 21 1998
Type I Interferon-mediated Stimulation of T Cells by CpG DNA
Siquan Sun,
Siquan Sun
From the *Department of Immunology, IMM4, The Scripps Research Institute, La Jolla, California 92037; ‡The R.W. Johnson Pharmaceutical Research Institute, San Diego, California 92121; and §The Edward Jenner Institute for Vaccine Research, Compton, Newbury, Berkshire, RG20 7NN, United Kingdom
Search for other works by this author on:
Xiaohong Zhang,
Xiaohong Zhang
From the *Department of Immunology, IMM4, The Scripps Research Institute, La Jolla, California 92037; ‡The R.W. Johnson Pharmaceutical Research Institute, San Diego, California 92121; and §The Edward Jenner Institute for Vaccine Research, Compton, Newbury, Berkshire, RG20 7NN, United Kingdom
Search for other works by this author on:
David F. Tough,
David F. Tough
From the *Department of Immunology, IMM4, The Scripps Research Institute, La Jolla, California 92037; ‡The R.W. Johnson Pharmaceutical Research Institute, San Diego, California 92121; and §The Edward Jenner Institute for Vaccine Research, Compton, Newbury, Berkshire, RG20 7NN, United Kingdom
Search for other works by this author on:
Jonathan Sprent
Jonathan Sprent
From the *Department of Immunology, IMM4, The Scripps Research Institute, La Jolla, California 92037; ‡The R.W. Johnson Pharmaceutical Research Institute, San Diego, California 92121; and §The Edward Jenner Institute for Vaccine Research, Compton, Newbury, Berkshire, RG20 7NN, United Kingdom
Search for other works by this author on:
Siquan Sun
From the *Department of Immunology, IMM4, The Scripps Research Institute, La Jolla, California 92037; ‡The R.W. Johnson Pharmaceutical Research Institute, San Diego, California 92121; and §The Edward Jenner Institute for Vaccine Research, Compton, Newbury, Berkshire, RG20 7NN, United Kingdom
Xiaohong Zhang
From the *Department of Immunology, IMM4, The Scripps Research Institute, La Jolla, California 92037; ‡The R.W. Johnson Pharmaceutical Research Institute, San Diego, California 92121; and §The Edward Jenner Institute for Vaccine Research, Compton, Newbury, Berkshire, RG20 7NN, United Kingdom
David F. Tough
From the *Department of Immunology, IMM4, The Scripps Research Institute, La Jolla, California 92037; ‡The R.W. Johnson Pharmaceutical Research Institute, San Diego, California 92121; and §The Edward Jenner Institute for Vaccine Research, Compton, Newbury, Berkshire, RG20 7NN, United Kingdom
Jonathan Sprent
From the *Department of Immunology, IMM4, The Scripps Research Institute, La Jolla, California 92037; ‡The R.W. Johnson Pharmaceutical Research Institute, San Diego, California 92121; and §The Edward Jenner Institute for Vaccine Research, Compton, Newbury, Berkshire, RG20 7NN, United Kingdom
Address correspondence to Jonathan Sprent, Department of Immunology, IMM4, The Scripps Research Institute, 10550 North Torrey Pines Rd., La Jolla, CA 92037. Phone: 619-784-8619; Fax: 619-784-8839; E-mail: [email protected]
Received:
August 31 1998
Revision Received:
October 21 1998
Online ISSN: 1540-9538
Print ISSN: 0022-1007
1998
J Exp Med (1998) 188 (12): 2335–2342.
Article history
Received:
August 31 1998
Revision Received:
October 21 1998
Citation
Siquan Sun, Xiaohong Zhang, David F. Tough, Jonathan Sprent; Type I Interferon-mediated Stimulation of T Cells by CpG DNA . J Exp Med 21 December 1998; 188 (12): 2335–2342. doi: https://doi.org/10.1084/jem.188.12.2335
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement